Analysis of whether Bortezomib is a proteasome inhibitor drug

Bortezomib is a typical proteasome inhibitor drug. Its mechanism of action is mainly by reversibly inhibiting the activity of the 26S proteasome, thereby blocking the degradation process of abnormal proteins in cells. This mechanism is of great significance in the treatment of malignant tumors such as multiple myeloma, because malignant cells are highly dependent on protein metabolism. Blockage of proteasome function will lead to protein accumulation in tumor cells and trigger cell apoptosis.

The proteasome is a complex enzyme system in cells responsible for degrading ubiquitin-tagged proteins. It plays a key role in multiple life processes such as cell cycle regulation, apoptosis signaling, and inflammation regulation. The emergence of bortezomib breaks the limitation that traditional chemotherapy drugs can only kill rapidly proliferating cells. It exerts anti-cancer effects by interfering with the intracellular protein balance mechanism, making it one of the representative drugs for proteasome-targeted therapy.

In clinical applications, bortezomib is mainly used to treat hematological malignancies such as multiple myeloma and mantle cell lymphoma. Compared with traditional chemotherapy drugs, bortezomib shows obvious advantages in improving progression-free survival and overall survival, especially for treatment-naïve and relapsed and refractory patients. At the same time, it can also be used in combination with other chemotherapy drugs such as lenalidomide and dexamethasone to enhance the synergistic effect of treatment.

Overall, bortezomib, as a proteasome inhibitor, has created a new direction in anti-tumor treatment. It induces malignant cell death by blocking protein degradation pathways, representing the successful practice of targeted therapy strategies in hematological tumors. In the future, with the continuous development of new generation proteasome inhibitors, drugs like bortezomib are expected to be applied in more tumor types.
Reference materials:https://www.drugs.com/donanemab.html

xa0